GLS and nonpapillary renal cell carcinoma: Notably, ccRCC relies on glutamine for tumour growth,47 which has led to the investigation of the glutaminase (GLS) inhibitor CB‐839 in a phase I clinical study with patients with advanced/metastatic ccRCC.48